| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.SCHRES.2016.07.018 |
| P8608 | Fatcat ID | release_bxs5np56mje5llz3m2c72gjtyy |
| P698 | PubMed publication ID | 27499361 |
| P50 | author | John M. Kane | Q52274733 |
| Christoph Correll | Q56954221 | ||
| Taishiro Kishimoto | Q87381303 | ||
| P2093 | author name string | Katsuhiko Hagi | |
| Fuminari Misawa | |||
| P433 | issue | 2-3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 220-230 | |
| P577 | publication date | 2016-08-04 | |
| P1433 | published in | Schizophrenia Research | Q7431607 |
| P1476 | title | Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics | |
| P478 | volume | 176 |
| Q64889462 | Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. |
| Q59336773 | Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis |
| Q46365588 | Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. |
| Q64967609 | Dilemmas in the treatment of early-onset first-episode psychosis. |
| Q60919880 | Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting |
| Q52641630 | Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study. |
| Q57074533 | Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients |
| Q59791864 | Haloperidol decanoate long-acting injection (HDLAI): Results of a 1-year mirror-image study |
| Q41658737 | Improving outcomes of first-episode psychosis: an overview |
| Q55438360 | Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. |
| Q93092613 | Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities |
| Q92241153 | National database study on the use of long-acting antipsychotic injections and hospital readmission proportions in patients with schizophrenia in Japan |
| Q38779397 | New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base. |
| Q55083271 | PROLACTIN LEVELS IN PATIENTS WITH SCHIZOPHRENIA WHO WERE SWITCHED FROM DAILY TO ONCE-MONTHLY ARIPIPRAZOLE TREATMENT. |
| Q92165500 | Pharmacological treatment of violence in schizophrenia |
| Q88688604 | Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate |
| Q38744570 | The Use of Long-Acting Injectable Antipsychotics in Schizophrenia |
| Q93333373 | The effects of different periods of co-administration of oral and long-acting injectable aripiprazole: A propensity score analysis |
| Q55023835 | What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? |
| Q92014619 | [Long-acting antipsychotics: The QAAPAPLE algorithm review] |
Search more.